Read by QxMD icon Read

Market access

Fikeremaryam Birara Feleke, Melaku Berhe, Getachew Gebru, Dana Hoag
The livestock sector serves as a foremost source of revenue for rural people, particularly in many developing countries. Among the livestock species, sheep and goats are the main source of livelihood for rural people in Ethiopia; they can quickly multiply, resilient and are easily convertible to cash to meet financial needs of the rural producers. The multiple contributions of sheep and goat and other livestock to rural farmers are however being challenged by climate change and variability. Farmers are responding to the impacts of climate change by adopting different mechanisms, where choices are largely dependent on many factors...
2016: SpringerPlus
Jay Pan, Hanqing Zhao, Xiuli Wang, Xun Shi
In 2009, the Chinese government launched a new round of healthcare reform, which encourages development of private hospitals. Meanwhile, many public hospitals in China also became increasingly profit-oriented. These trends have led to concerns about social justice and regional disparity. However, there is a lack of empirical scientific analysis to support the debate. We started to fill this gap by conducting a regional-level analysis of spatial variation in spatial access to hospitals in the Sichuan Province...
October 1, 2016: Social Science & Medicine
Georgi Iskrov, Tsonka Miteva-Katrandzhieva, Rumen Stefanov
BACKGROUND: Limited resources and expanding expectations push all countries and types of health systems to adopt new approaches in priority setting and resources allocation. Despite best efforts, it is difficult to reconcile all competing interests, and trade-offs are inevitable. This is why multi-criteria decision analysis (MCDA) has played a major role in recent uptake of value-based reimbursement. MCDA framework enables exploration of stakeholders' preferences, as well as explicit organization of broad range of criteria on which real-world decisions are made...
2016: Frontiers in Public Health
S Vincent Rajkumar, Jean Luc Harousseau
Advances in the diagnosis and treatment of multiple myeloma have come at a rapid pace, especially with several new drugs entering the market in the last few years. However access and affordability to new treatments poses a major challenge, both in the United States and around the world. High costs of life-saving drugs are detrimental to both the personal finances of the individual patient, as well as society which must bear the increasing costs in terms of increased health insurance premiums, taxes, or both...
October 14, 2016: Blood
Aastha Gupta, Sandeep Juneja, Marco Vitoria, Vincent Habiyambere, Boniface Dongmo Nguimfack, Meg Doherty, Daniel Low-Beer
With anti-retroviral treatment (ART) scale-up set to continue over the next few years it is of key importance that manufacturers and planners in low- and middle-income countries (LMICs) hardest hit by the HIV/AIDS pandemic are able to anticipate and respond to future changes to treatment regimens, generics pipeline and demand, in order to secure continued access to all ARV medicines required. We did a forecast analysis, using secondary WHO and UNAIDS data sources, to estimate the number of people living with HIV (PLHIV) and the market share and demand for a range of new and existing ARV drugs in LMICs up to 2025...
2016: PloS One
W Kievit, F A C Berden, J P H Drenth
Pharmaceutical companies are under increasing scrutiny because of their strategy for gaining market access and reimbursement authorisation for novel drugs. The tool most often used is that of a randomised controlled trial (RCT) in a highly selected population that has a high chance of responding on the treatment but a low chance of developing side effects. This population differs to a large extent from real-life patients, who have diverging characteristics that can influence effectiveness and safety; these include co-morbidity, age and disease severity...
2016: Nederlands Tijdschrift Voor Geneeskunde
Richard Whale, Michael Harris, Gail Kavanagh, Vijitha Wickramasinghe, Christopher I Jones, Steven Marwaha, Ketan Jethwa, Nirmalan Ayadurai, Andrew Thompson
BACKGROUND: One year of antipsychotic treatment from symptom remission is recommended following a first episode of psychosis (FEP). AIMS: To investigate the effectiveness of commonly used antipsychotic medications in FEP. METHOD: A retrospective cohort study of naturalistic treatment of patients (N=460) accepted by FEP services across seven UK sites. Treatment initiation to all-cause discontinuation determined from case files. RESULTS: Risk of treatment discontinuation is greatest within 3 months of treatment initiation...
September 2016: BJPsych Open
Abu Nasar, Aminoor Rahman, Nazmul Hoque, Anup Kumar Talukder, Ziban Chandra Das
AIM: To investigate the status, problems and prospects of Japanese quail (Coturnix coturnix japonica) farming in selected areas of Bangladesh. MATERIALS AND METHODS: The study was conducted in 14 districts of Bangladesh, viz., Dhaka, Narayanganj, Munshiganj, Mymensingh, Netrakona, Faridpur, Jessore, Khulna, Satkhira, Kushtia, Bogra, Naogaon, Comilla, and Sylhet during the period from July 2011 to June 2012. A total of 52 quail farmers were interviewed for data collection using a structured questionnaire...
September 2016: Veterinary World
Arka Chattopadhyay, Stephen Frey, Ghiselle Green
BACKGROUND: Bifeprunox is a novel antipsychotic drug designed to treat schizophrenia. However, research into the drug was ceased in 2009 due to rejection of licence to go to market by the US Food and Drug Administration (FDA), who could not approve the drug for acute or long-term symptoms of schizophrenia because more research was required to demonstrate convincing effects "beyond those already achieved" with currently licenced drugs. There were also concerns expressed over one death of a person whilst on the drug...
October 12, 2016: Cochrane Database of Systematic Reviews
Francis Mbuza, Rosine Manishimwe, Janvier Mahoro, Thomas Simbankabo, Kizito Nishimwe
A study was conducted on 37 randomly selected broiler poultry farmers in Rwanda to characterize the production system using pre-tested semi-structured questionnaires. The data were processed in SPSS and presented as means, percentages and ranges in tables and text. All respondents kept Cobb breed and young stock was mainly (73 %) imported from abroad. The majority of respondents were males (68 %) and most farmers had attended only primary level of education (40.5 %). Most of the farms were in the peri-urban (48...
October 11, 2016: Tropical Animal Health and Production
Paul C Pearlman, Rao Divi, Michael Gwede, Pushpa Tandon, Brian S Sorg, Miguel R Ossandon, Lokesh Agrawal, Vinay Pai, Houston Baker, Tiffani Bailey Lash
Point-of-care (POC) technologies have proved valuable in cancer detection, diagnosis, monitoring, and treatment in the developed world, and have shown promise in low-and-middle-income countries (LMIC) as well. Despite this promise, the unique design constraints presented in low-resource settings, coupled with the variety of country-specific regulatory and institutional dynamics, have made it difficult for investigators to translate successful POC cancer interventions to the LMIC markets. In response to this need, the National Cancer Institute has partnered with the National Institute of Biomedical Imaging and Bioengineering to create the National Institutes of Health Affordable Cancer Technologies (ACTs) program...
2016: IEEE Journal of Translational Engineering in Health and Medicine
Steven Jarrett, Theodor Dingermann
BACKGROUND: Pharmacists are the recognized experts in pharmacotherapy. With the recent introduction of biosimilar agents into the US market, pharmacists are poised to play a pivotal role in evaluating their risks versus benefits within the framework of cost containment. PURPOSE: This article provides hospital pharmacists with the necessary information on the principles surrounding the development, approval process, and use of biosimilars. METHODS: Information contained in this article enables hospital pharmacists to identify concerns relating to biosimilars, implement educational components, and successfully evaluate biosimilars for the addition to the formulary...
November 2015: Hospital Pharmacy
Silvio Danese, Stefanos Bonovas, Laurent Peyrin-Biroulet
Biologic agents have revolutionized the care management of many life-threatening and debilitating diseases. As patents for older biologic therapies have begun to expire, the market has opened to copy versions of the originators - commonly referred to as biosimilars, follow-on biologic agents or subsequent-entry biologic agents - which are expected to gain a portion of the market, reduce health-care spending and increase treatment access worldwide. Importantly for patients with IBD, CT-P13 was the first biosimilar to infliximab that obtained regulatory approval by the European Medicines Agency in September 2013 and by the FDA in April 2016...
October 12, 2016: Nature Reviews. Gastroenterology & Hepatology
W D Ludwig, S Dicheva
Biosimilar medicinal products (biosimilars) have been available in Europe for 10 years, allowing a wide use particularly in oncology. Biosimilars are being developed and approved by means of scientifically sound principles to assure close similarity with the reference products with regard to quality, efficacy, and safety. The scientific principles for establishing biosimilarity are the same as those for demonstrating comparability after a change in the manufacturing process of an already licensed biological...
October 10, 2016: Zeitschrift Für Gastroenterologie
Martin C Boonstra, Susanna W L de Geus, Hendrica A J M Prevoo, Lukas J A C Hawinkels, Cornelis J H van de Velde, Peter J K Kuppen, Alexander L Vahrmeijer, Cornelis F M Sier
Tumor targeting is a booming business: The global therapeutic monoclonal antibody market accounted for more than $78 billion in 2012 and is expanding exponentially. Tumors can be targeted with an extensive arsenal of monoclonal antibodies, ligand proteins, peptides, RNAs, and small molecules. In addition to therapeutic targeting, some of these compounds can also be applied for tumor visualization before or during surgery, after conjugation with radionuclides and/or near-infrared fluorescent dyes. The majority of these tumor-targeting compounds are directed against cell membrane-bound proteins...
2016: Biomarkers in Cancer
Hiromasa Okayasu, Carolyn Sein, Ahd Hamidi, Wilfried A M Bakker, Roland W Sutter
The Global Polio Eradication Initiative (GPEI) has seen significant progress since it began in 1988, largely due to the worldwide use of oral poliovirus vaccine (OPV). In order to achieve polio eradication the global cessation of OPV is necessary because OPV contains live attenuated poliovirus, which in rare circumstances could re-gain wild poliovirus (WPV) characteristics with potential to establish transmission. The GPEI endgame strategy for the period 2013-2018 recommends the globally synchronised sequential cessation of the Sabin strains contained in the OPV, starting with type 2 Sabin...
October 5, 2016: Biologicals: Journal of the International Association of Biological Standardization
Weerapong Thanapongtharm, Catherine Linard, Pornpiroon Chinson, Suwicha Kasemsuwan, Marjolein Visser, Andrea E Gaughan, Michael Epprech, Timothy P Robinson, Marius Gilbert
BACKGROUND: In Thailand, pig production intensified significantly during the last decade, with many economic, epidemiological and environmental implications. Strategies toward more sustainable future developments are currently investigated, and these could be informed by a detailed assessment of the main trends in the pig sector, and on how different production systems are geographically distributed. This study had two main objectives. First, we aimed to describe the main trends and geographic patterns of pig production systems in Thailand in terms of pig type (native, breeding, and fattening pigs), farm scales (smallholder and large-scale farming systems) and type of farming systems (farrow-to-finish, nursery, and finishing systems) based on a very detailed 2010 census...
October 6, 2016: BMC Veterinary Research
Peter Cnudde, Ola Rolfson, Szilard Nemes, Johan Kärrholm, Clas Rehnberg, Cecilia Rogmark, John Timperley, Göran Garellick
BACKGROUND: Sweden offers a unique opportunity to researchers to construct comprehensive databases that encompass a wide variety of healthcare related data. Statistics Sweden and the National Board of Health and Welfare collect individual level data for all Swedish residents that ranges from medical diagnoses to socioeconomic information. In addition to the information collected by governmental agencies the medical profession has initiated nationwide Quality Registers that collect data on specific diagnoses and interventions...
October 4, 2016: BMC Musculoskeletal Disorders
Harinder Singh Chahal, Farrah Kashfipour, Matt Susko, Neelam Sekhri Feachem, Colin Boyle
Medicines Regulatory Authorities (MRAs) are an essential part of national health systems and are charged with protecting and promoting public health through regulation of medicines. However, MRAs in resource-constrained settings often struggle to provide effective oversight of market entry and use of health commodities. This paper proposes a regulatory value chain model (RVCM) that policymakers and regulators can use as a conceptual framework to guide investments aimed at strengthening regulatory systems. The RVCM incorporates nine core functions of MRAs into five modules: (i) clear guidelines and requirements; (ii) control of clinical trials; (iii) market authorization of medical products; (iv) pre-market quality control; and (v) post-market activities...
May 2016: Revista Panamericana de Salud Pública, Pan American Journal of Public Health
Lisa Murray, Antonio Arias, Jibin Li, Sid Bhoopathy, Ismael J Hidalgo
To improve the quality of pharmaceutical products in their markets, several Latin American countries have begun to require that new generic products demonstrate bioequivalence against innovator or reference products. However, given the number of products involved, it is not feasible to rely on clinical studies to comply with this requirement. Instead, it makes sense to adopt or develop strategies that are appropriate to the characteristics of the region. To streamline drug development and accelerate patients' access to quality drug products, 15 years ago the United States Food and Drug Administration (FDA) decided to grant exemptions from clinical bioequivalence studies (i...
August 2016: Revista Panamericana de Salud Pública, Pan American Journal of Public Health
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"